DONATE NOW
Image
  • About Us
    • About
    • Board of Directors
    • Leadership
    • Contact
  • Our Impact
    • US Advocacy
    • Global Advocacy
    • Affinity Groups
    • Federation
    • AHF Research
  • Our Services
  • Global Programs
  • Media
    • News
    • Photos
    • Videos
    • AHF Films
  • Careers
  • Take Action
  • Find a Provider
View Post

Advocates Shout “No More!” to Greedy Gilead

In Advocacy, Gilead, News, Pharmaceutical by Fiona IpDecember 16, 2022

In case you missed it – AHF advocates protested at three Gilead Sciences’ offices in as many U.S. cities as part of nationwide World AIDS Day actions on Dec. 1! …

View Post

AHF Labels Gilead ‘War Profiteer’ and ‘Greedy Bastards!’ as Company Prices COVID Drug at $2K to $3K

In Featured, Gilead, News by Ged KensleaJune 30, 2020

In May, AIDS Healthcare Foundation demanded that the drug company price remdesivir, the newly approved drug for treating COVID-19—which Gilead had developed years earlier with $70M in government funding as …

View Post

AHF Demands Gilead Price Remdesivir at $1.00 per Dose

In Featured, Gilead, News by Ged KensleaMay 12, 2020

WASHINGTON (May 12, 2020) AIDS Healthcare Foundation (AHF) today demanded that remdesivir, the newly approved drug for treating COVID-19, be priced at no more than one U.S. dollar per dose.  …

View Post

AHF Welcomes U.S. Reps. Doggett and DeLauro’s Inquiry re: Gilead’s Use of Public Funds Developing COVID-19 Treatment

In Featured, Gilead, News by Ged KensleaMay 4, 2020

WASHINGTON (May 4, 2020) AIDS Healthcare Foundation (AHF) today praised the work of U.S. Representatives Lloyd Doggett (D-TX) and Rosa DeLauro (D-CT) for their demand for an accounting of how …

View Post

AHF Signs On to Open Letter to Gilead Urging Access to Remdesivir as COVID-19 Treatment

In Featured, Gilead, News by Ged KensleaMarch 30, 2020

Mr Daniel O’Day Chief Executive Officer Gilead Science, Inc. Dear Mr O’Day, Open letter to Gilead concerning ensuring access to remdesivir We write to request that Gilead take immediate actions …

View Post

AHF Demands Gilead Drop Exclusive ‘Orphan Drug’ Claim on COVID-19 Treatment

In Featured, Gilead, News by Ged KensleaMarch 25, 2020

In an unconscionable move amidst the unfolding global pandemic, Gilead Sciences, Inc. is using publicly funded research for an exclusive ‘orphan drug’ monopoly designation on a possible COVID-19 treatment   …

View Post

AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs

In Featured, Gilead, News by Ged KensleaJuly 16, 2019

Demand for compensation fund comes as another lawsuit against Gilead on behalf of 40 plaintiffs who have been injured from Gilead’s TDF-based drugs was filed Friday in Alameda County. Legal …

View Post

41 HIV and PrEP Patients File California Personal Injury Lawsuit Over Gilead’s TDF-Based Drugs

In Gilead, Global Featured by Ged KensleaApril 11, 2019

LOS ANGELES (April 11, 2018) 41 patients from 12 states nationwide who are living with HIV or AIDS or were on PrEP filed a personal injury lawsuit against Gilead Sciences …

View Post

Victory over Gilead! California Court Rules HIV Drug Personal Injury Cases May Proceed

In Featured, Gilead by K PakFebruary 13, 2019

Superior Court of California, County of Los Angeles rejects all but one of Gilead’s arguments in demurrer seeking to have personal injury cases over its promotion of TDF-based HIV/AIDS medications …

View Post

In case you missed it: Official DRUG$ Launch!

In Gilead, Global Advocacy, Pharmaceutical by Fiona IpJanuary 24, 2019

Narrated by Academy Award® Winner J.K. Simmons, “DRUG$” is a feature-length documentary about Big Pharma greed and the soaring price of medicines in the United States. In a titanic struggle …

  • Page 1 of 2
  • 1
  • 2
  • →
Cutting edge medicine and advocacy regardless of ability to pay
Helpful Links

Find A Doctor
Donate Now
Contact Us
Careers at AHF

Press Inquiries
AHF Resources

AHF Connect
Email Portal

AHF Billboards
Financials & Transparency
Submit Complaint or Grievance

Health at AHF

HIVcare.org
AHFpharmacy.org
FreeSTDcheck.org
FreeHIVtest.net
PositiveHealthcare.net

Quick Links

Healthy Housing Foundation
Housing is a Human Right
Out of the Closet
AHF Speak Out
Global Programs
AHF Institute

Sitemap
Notice of Privacy Practices
Data Protection and Privacy
Web Privacy Policy
Forbes 2026 America's Best Large Employers logoImage

© Copyright 2026 AIDS Healthcare Foundation is a nonprofit, tax-exempt 501(C)(3) organization.
Cutting edge medicine and advocacy regardless of ability to pay
Helpful Links

Find A Doctor
Donate Now
Contact Us
Careers at AHF

Press Inquiries
AHF Resources

AHF Connect
Email Portal

AHF Billboards
Financials & Transparency
Submit Complaint or Grievance

Health at AHF

HIVcare.org
AHFpharmacy.org
FreeSTDcheck.org
FreeHIVtest.net
PositiveHealthcare.net

Quick Links

Healthy Housing Foundation
Housing is a Human Right
Out of the Closet
AHF Speak Out
Global Programs
AHF Institute


Sitemap
Notice of Privacy Practices
Web Privacy Policy
Data Protection and Privacy
© Copyright 2026 AIDS Healthcare Foundation is a nonprofit, tax-exempt 501(C)(3) organization.
Forbes 2026 America's Best Large Employers logo
Image
  • About Us
    • About
    • Board of Directors
    • Leadership
    • Contact
  • Our Impact
    • US Advocacy
    • Global Advocacy
    • Affinity Groups
    • Federation
    • AHF Research
  • Our Services
  • Global Programs
  • Media
    • News
    • Photos
    • Videos
    • AHF Films
  • Careers
  • Take Action
  • Find a Provider

Press Inquiries - US
Ged Kenslea, AHF Senior Director, Communications
(323) 791-5526
[email protected]

Imara Canady, AHF National Communications Director
(770) 940-6555
[email protected]

Press Inquiries - Global
Denys Nazarov, AHF Director of Global Policy & Comms.
(323) 219-1091
[email protected]

Press Inquiries - US
Ged Kenslea, AHF Senior Director, Communications
(323) 791-5526
[email protected]

Imara Canady, AHF National Communications Director
(770) 940-6555
[email protected]

Press Inquiries - Global
Denys Nazarov, AHF Director of Global Policy & Comms.
(323) 219-1091
[email protected]

    • English
    • Spanish
    • Chinese
    • Filipino
    • Vietnamese
    • Arabic
    • French
    • Korean
    • Russian
    • Haitian Creole
    • Portuguese